FOLD Amicus Therapeutics
- 9.310
- +0.270+2.99%
Amicus Therapeutics News
This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Jefferies a
Guggenheim: Amicus Therapeutics (FOLD.US) rating was raised, adjusted from neutral to buy, with a target price of $13.00.
Guggenheim: Amicus Therapeutics (FOLD.US) rating was raised, adjusted from neutral to buy, with a target price of $13.00.
Guggenheim Upgrades Amicus Therapeutics to Buy From Neutral With $13 Price Target
Amicus Therapeutics (FOLD) has an average outperform rating and a price target range of $13 to $21, according to analysts polled by Capital IQ. Price: 9.44, Change: +0.40, Percent Change: +4.42
Amicus Therapeutics Is Maintained at Buy by UBS
Amicus Therapeutics Is Maintained at Buy by UBS
UBS: Maintains Amicus Therapeutics (FOLD.US) rating, adjusted from buy to buy rating, and adjusted target price from $20.00 to $19.00.
UBS: Maintains Amicus Therapeutics (FOLD.US) rating, adjusted from buy to buy rating, and adjusted target price from $20.00 to $19.00.
UBS Maintains Buy on Amicus Therapeutics, Lowers Price Target to $19
UBS analyst Karl Chalabala maintains Amicus Therapeutics (NASDAQ:FOLD) with a Buy and lowers the price target from $20 to $19.
Amicus Therapeutics Inc (FOLD) Q1 2024 Earnings: Surpasses Revenue Estimates and Projects ...
Amicus Therapeutics Price Target Cut to $19.00/Share From $20.00 by Morgan Stanley
Amicus Therapeutics Price Target Cut to $19.00/Share From $20.00 by Morgan Stanley
UBS Trims Price Target on Amicus Therapeutics to $19 From $20, Keeps Buy Rating
Amicus Therapeutics (FOLD) has an average rating of outperform and price targets ranging from $13 to $22, according to analysts polled by Capital IQ. Price: 9.22, Change: -0.26, Percent Change: -2.74
Amicus Therapeutics Is Maintained at Buy by B of A Securities
Amicus Therapeutics Is Maintained at Buy by B of A Securities
B of A Securities Maintains Buy on Amicus Therapeutics, Lowers Price Target to $13
B of A Securities analyst Tazeen Ahmad maintains Amicus Therapeutics (NASDAQ:FOLD) with a Buy and lowers the price target from $14 to $13.
Needham Reiterates Hold on Amicus Therapeutics
Needham analyst Gil Blum reiterates Amicus Therapeutics (NASDAQ:FOLD) with a Hold.
Amicus Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 — Needham Reiterates → Hold 03/18/2024 101.48% JP Morgan $21 → $19 Maintains Overweight 02/29/
Amicus Therapeutics (FOLD) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Amicus Therapeutics | 10-Q: Quarterly report
Amicus Therapeutics Shares Are Trading Lower Following Mixed Q1 Earnings.
Amicus Therapeutics Shares Are Trading Lower Following Mixed Q1 Earnings.
Amicus Therapeutics: Q1 Earnings Snapshot
Amicus Therapeutics: Reiterating Full-Yr Non-GAAP Profitability Projected in 2024 >FOLD
Amicus Therapeutics: Reiterating Full-Yr Non-GAAP Profitability Projected in 2024 >FOLD
Amicus Therapeutics: Guiding to Full-Yr 2024 Total Rev Growth of 25%-30% at CER >FOLD
Amicus Therapeutics: Guiding to Full-Yr 2024 Total Rev Growth of 25%-30% at CER >FOLD
Amicus Forecasts 2024 Total Revenue Growth Of 25%-30%, With Galafold Revenue Growth Of 13%-17%
Amicus Forecasts 2024 Total Revenue Growth Of 25%-30%, With Galafold Revenue Growth Of 13%-17%
Analysis
Price Target
No Data
